Capricor Therapeutics Stock Forecast
NASDAQ: CAPRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 8.00 -1.23%
CAPR analyst consensus
Consensus (10 analysts)
buy
Avg. price target
$27.00+233.33%
- Strong buy 1
- Buy 3
- Hold 6
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 10 Wall Street analysts covering Capricor Therapeutics (2026-10-08), 4 rate the stock a buy or strong buy, 6 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $27.00, with a high estimate of $54.00 and a low estimate of $7.00. The average target implies upside of 233.3% from the current price of $8.10.
The spread between the highest and lowest targets is 671.4%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for CAPR.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 10% |
| Buy | 3 | 30% |
| Hold | 6 | 60% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $7.00 | -13.58% |
| Average target | $27.00 | +233.33% |
| High target | $54.00 | +566.67% |